

Living with Thalassaemia Thalassaemia Treatment

Prof. Yesim AYDINOK Ege University Hospital Department of Paediatric Haematology Director of Hospital Blood Bank Izmir - Turkey

17 March 2013 Copenhagen

Treatment strategies in Thalassaemia

Key elements of treatment

- Transfusion
- Iron chelation
- Supportive treatments
- Splenectomy
- Monitoring and managing organ disturbances
- Prevention and treatment of infections

Cure

• Stem cell transplantation

Treatment strategies in Thalassaemia


Key elements of treatment

- Transfusion
- Iron chelation
- Supportive treatments
- Splenectomy
- Monitoring and managing complications
 - cardiac, liver, endocrine
- Prevention and treatment of infections

Cure

• Stem cell transplantation

Why do thalassaemia patients need transfusion?




Normal red cells

Abnormal red cells are produces and breakdown easily

> severe anaemia

Red cells of thalassaemia patients




growth is impaired

- quality of life is diminished
- spleen size increases progressively
- cranial and a facial distortion

Spectrum of transfusion requirement in thalassaemia


β-Thalassaemia intermedia



β-thalassaemia major

Sources of iron accumulation in thalassaemias

Thalassaemia intermedia



Increased absorption of iron (primary source of iron) 4 mg/day

Episodic transfusion (secondary source of iron)

- surgeries
- pregnancy
- infections
- etc.

Thalassaemia major



Regular blood transfusions (primary source of iron)

- 1 unit blood contains 200 mg iron
- Transfusions by 2-4 units/month
- Annual intake; 5000-10000 mg

Increased absorption of iron (secondary source of iron)

The body has no mechanism for excreting excess iron

Under normal conditions, iron absorption and loss are balanced at ~1mg/day

Organ systems susceptible to iron overload

Clinical sequel of iron overload

Pituitary \rightarrow impaired growth & puberty

- Thyroid \rightarrow hypothyroidism
- Heart \rightarrow cardiac failure
- Liver \rightarrow hepatic failure
- Pancreas \rightarrow diabetes mellitus
- Gonads \rightarrow diminishes sexual function

Untreated iron overload results in damage to the liver, hormon secreting glands and most importantly to the heart

The assessment and monitoring of iron burden

Optimal balance

iron overload

iron depletion

inadequate iron chelation can not prevent iron overload and is resulted with organ damage over chelation may lead to depletion of iron that is needed for normal tissue metabolism

Assessment of body iron stores

Serum ferritin

- Representative of storage iron
- Easy to measure from 1 spoon blood
- monthly or bi-monthly monitoring is recommended

Measurement of organ iron stores by MRI machine

- liver iron concentration;
 - yearly monitoring whenever available
- cardiac iron;
 - yearly monitoring after 10 years old




Management of iron clearance therapy in thalassemia major

Iron clearance therapy is started when;

- patients have received 10-20 times blood transfusions
- serum ferritin reaches to 1000 μ g/L
- liver iron exceeds 3.2 mg iron
- and maintained;

Serum Ferritin (µg/L)	Liver iron (mg Fe/ g dw)	Cardiac iron (ms)	Body iron burden
<100	0.6–1.2	>20	Normal
500-1000	3.2–7.0	>20	Optimal
1000-2500	> 7.0–15	10-20	Moderate
>2500	> 15	<10	Severe

Evolution of iron chelation therapy




Comparison of iron chelators

Property	® Desferal	® Ferriprox	® Exjade
Usual dose	20–60 mg/kg/day	75–100 mg/kg/day	10–40 mg/kg/day
2-6 years-old	first-line	limited experience	second line*
>6 years old	first-line	second line	first-line
Side effects	local reactions, eye & ear toxicity bone abnormalities Yersinia infections	prone to infection (1%) abdominal discomfort nausea, vomiting (30%) joint pain(4-40%) liver (7%) zinc deficiency	abdominal discomfort nausea, vomiting (15%) transient rash (12%) liver (8%) kidney toxicity (6%)
Advantages	long term experience	best for cardiac iron	once daily dosing effective in removal of liver and heart iron
Disadvantages	compliance	less effective in liver weekly blood count	cost

* First line in US and rest of the world

Cardiac iron overload-related mortality is no longer a leading cause of death




Mortality rates per cohort

Use of modern iron chelation therapy and regular CMR monitoring has dramatically reduced the cardiac iron overload-related mortality in the Red Cell Disorders Unit

BMT, bone marrow transplantation;

In 2 UK centers, about 50% of patients with β-thalassaemia currently receive oral iron chelators (Ferriprox and Exjade)



Current chelation practice of patients with β-thalassaemia in Ege University Thalassaemia Center

